Transaction Overview 交易概览

• Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China

Biosplice Therapeutics和海思科医药集团股份有限公司，宣布达成一项独家许可协议。Biosplice 授予海思科在中国独家开发和商业化用于治疗膝骨关节炎（“OA”）和其他肌肉骨骼疾病的药物Lorecivivint（SM04690）的权利。

• Haisco will lead development, regulatory and commercialization activities for lorecivivint in China. Deal terms include $140 million in aggregate value plus royalties on future sales, including a combination of upfront payment, clinical and commercial milestones.

根据协议，海思科将独家负责Lorecivivint在中国的开发、注册和商业化。交易条款总对价最高可达1.4亿美元，包括2000万美金的首付款和注册里程碑，以及一定的销售里程碑和未来销售的特许权使用费。

• YAFO Capital (Shanghai) acted as exclusive financial advisors on this transaction for Biosplice Therapeutics. 

上海雅法资产管理有限公司担任Biosplice Therapeutics的独家财务顾问。

September, 2021 – Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, and Haisco Pharmaceutical Group Co., Ltd. (“Haisco”), a pharmaceutical company based in the People’s Republic of China (“China”), announced the execution of a licensing agreement which grants Haisco the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) and other musculoskeletal conditions in China.

2021年9月10日，Biosplice Therapeutics, Inc. (“Biosplice”), 一家专注临床阶段创新药物的美国生物科技公司，该公司致力于为重大疾病患者提供基于选择性前体mRNA剪接的疗法，和海思科医药集团股份有限公司，宣布达成一项独家许可协议。Biosplice 授予海思科在中国独家开发和商业化用于治疗膝骨关节炎（“OA”）和其他肌肉骨骼疾病的药物Lorecivivint（SM04690）的权利。

YAFO Capital (Shanghai) acted as exclusive financial advisors on this transaction for Biosplice Therapeutics.

上海雅法资产管理有限公司担任Biosplice Therapeutics的独家财务顾问。

Lorecivivint, in development as a potential disease-modifying osteoarthritis drug with durable and meaningful clinical benefit, has the potential to be the first novel drug therapy for osteoarthritis in nearly 20 years. An investigational CLK/DYRK kinase inhibitor that modulates the Wnt pathway, lorecivivint is currently being evaluated in Phase 3 pivotal trials for the treatment of knee osteoarthritis in the United States. In Phase 2 studies, lorecivivint demonstrated significant and long-term improvements on patient reported outcomes relating to pain and function.  Lorecivivint also showed structural benefit, as measured by X-ray analysis of medial joint space width, 52 weeks following a single injection in the target knee. Lorecivivint has appeared safe and well-tolerated in studies to date.

Lorecivivint是Biosplice公司正在开发的有可能成为近年来首个获批用于骨关节功能改善的新机制创新药。它是一种调节Wnt通路CLK/DYRK激酶抑制剂，目前正在美国进行治疗膝骨关节炎的III期临床试验。在II期临床试验中，Lorecivivint已显示出与疼痛和骨关节功能相关的显著疗效和长期改善疾病的潜力。通过X射线测量分析单次注射后52周的内侧关节间隙宽度，Lorecivivint展示了其在骨关节结构上改善的益处。迄今为止，Lorecivivint在研究中被证明安全且耐受性良好。

Erich Horsley, Chief Financial Officer of Biosplice, commented, “China has become one of the most important pharmaceutical markets in the world, and we are pleased to partner with Haisco, an established leader in pain-management, in this important geography. This marks an important next step in our plan to maximize the global potential of lorecivivint by partnering with well-established, regional partners in key markets. We look forward to working with Haisco to bring hope to the millions of osteoarthritis patients in China as we launch lorecivivint in the coming years.”

Biosplice首席财务官Erich Horsley表示：“中国已成为世界上最重要的医药市场之一，我们很高兴能在这个重要的地区与疼痛管理领域的知名企业海思科合作。通过与海思科的合作，我们将实现Lorecivivint在全球商业布局中非常的重要一步。我们非常期待与海思科的合作并在未来几年推出Lorecivivint，让中国超过数百万的骨关节炎患者获益。”

 “Pain management has always been one of the key disease areas of Haisco. China has the largest population of osteoarthritis patients in the world but the existing treatments are limited in terms of being effective at the same time being safe,” said General Manager of Haisco  R&D Center, Dr. Pangke Yan. “Haisco is pleased to cooperate with a world-leading innovative drug company like Biosplice to develop and commercialize this potential first-in-class osteoarthritis drug in China. This collaboration helps to grow Haisco’s portfolio and also brings hope to patients who are waiting for new therapies. Haisco will quickly promote Lorecivivint to China market with its expertise in development and commercialization built in the past 20 years.”

海思科研发中心总经理严庞科博士表示，“疼痛管理一直是海思科布局的重要疾病领域之一，同时中国也有全世界最庞大的骨关节炎患者群体，且现有治疗方法的有效性和安全性存在未满足的临床需求。海思科很高兴与Biosplice这样全球领先的创新药研发公司合作，海思科研发中心总经理严庞科博士表示，“疼痛管理一直是海思科布局的重要疾病领域之一，同时中国也有全世界最庞大的骨关节炎患者群体，且现有治疗方法的有效性和安全性存在未满足的临床需求。海思科很高兴与Biosplice这样全球领先的创新药研发公司合作，在中国地区开发和商业化全球首创新药Lorecivivint。

Haisco will lead development, regulatory and commercialization activities for lorecivivint in China. Deal terms include $140 million in aggregate value plus royalties on future sales, including a combination of upfront payment, clinical and commercial milestones. Shanghai Yafo Capital Asset Management Co., Ltd. advised Biosplice on the transaction.

根据协议，海思科将独家负责Lorecivivint在中国的开发、注册和商业化。交易条款总对价最高可达1.4亿美元，包括2000万美金的首付款和注册里程碑，以及一定的销售里程碑和未来销售的特许权使用费。

About ImmuneOncia Therapeutics, Inc.

ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan Corporation in South Korea and Sorrento Therapeutics, Inc. inU.S. ImmuneOncia leverages both companies’ expertise in drug development and antibody engineering. The company’s mission is to bring safe, effective, and novel immunotherapies to oncology patients world-wide, and its portfolio includes diverse immune checkpoint antibodies. ImmuneOncia has successfully completed a Phase I study of IMC-001, its leading candidate anti-PDL1 antibody,and a Phase II study was initiated in 2H 2020.For more information, please visit www.immuneoncia.com

ImmuneOncia是一家以肿瘤免疫为核心的生物制药公司。ImmuneOncia是韩国Yuhan公司和美国Sorrento Therapeutics公司于2016年组建的合资公司。ImmuneOncia充分利用了两家公司在药物开发和抗体工程方面的优势，为全球肿瘤患者提供安全、有效的新型免疫疗法，其产品组合包括多种免疫检查点抗体。ImmuneOncia已完成其核心产品PD-L1抗体IMC-001的I期临床研究，并于2020年下半年启动II期临床研究。更多信息，请访问：www.immuneoncia.com

About Lorecivivint

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates the Wnt pathway and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: generation of cartilage, slowing of cartilage breakdown, and reduction of inflammation.

Additional information on Biosplice’s investigational lorecivivint osteoarthritis program can be found here:

https://www.biosplice.com/clinical-development/detail.aspx?id=20

Lorecivivint(SM04690)是一种小分子CLK/DYRK1A抑制剂，可调节Wnt通路，作为一种潜在的改善疾病的骨关节炎药物进行开发。相关临床前和临床数据表明，Lorecivivint具有双重作用机制，对关节健康具有三种潜在影响：生成软骨、减缓软骨分解和减少炎症。有关Biosplice研究性药物Lorecivivint骨关节炎项目的更多信息，请访问 https://www.biosplice.com/clinicaldevelopment/detail.aspx?id=20

About Biosplice Therapeutics

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions. Learn more at https://www.biosplice.com.

Biosplice是一家专注临床阶段创新药物的美国生物科技公司，正在开发基于开创性选择性前体mRNA剪接技术的首创小分子疗法。基于Wnt通路调节的基础发现，Biosplice阐明了将CLK/DYRK激酶与选择性剪接的治疗调节联系起来的新生物学。选择性剪接是一种重要的生物学机制，可调节细胞中蛋白质的多样化，进而决定细胞类型和功能。Biosplice的临床开发药物包括用于治疗骨关节炎的Lorecivivint、用于多种癌症的Cirtuvivint，以及包含阿尔茨海默病及其他退行性疾病的广泛产品线。了解更多信息，请访问：https://www.biosplice.com

About Haisco Pharmaceuticals 海思科制药

Haisco Pharmaceutical Group is a China-based public pharmaceutical company dedicated to providing the best medical products in specialized area to patients and our community. With extensive experience, Haisco is capable of developing, manufacturing and commercializing innovative drug products as well as generic drug products with high technical barrier in our focused areas.

海思科医药集团股份有限公司是一家总部位于中国的上市制药公司（股票代码 002653），致力于为患者和我们的社区提供专业领域最好的医疗产品。公司管线涉及麻醉及镇痛、糖尿病及并发症、肿瘤、呼吸等多个疾病领域，在创新药、高端仿制药等专业领域启动了数十个新项目的研究开发。公司自主研发的中国首个全新的具有自主知识产权的静脉麻醉药物，1类创新药环泊酚注射液于 2020 年 12 月获批上市。凭借丰富的经验，海思科有能力在我们的重点领域开发、制造和商业化创新药产品以及高技术壁垒仿制药。了解更多海思科的信息，请访问：http://www.haisco.com/

About YAFO Life Sciences 雅法全球医疗

YAFO Life Sciences (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗（YAFO Life Sciences）是雅法资本旗下的医疗大健康部门，专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作；为中国医疗企业提供产品全球授权、海外市场研究服务，寻找海外投资并购标的，及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验；雅法庞大的海外的区域合伙人团队，均具20+年医药行业及交易经验，覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系：黎琦 | BD Director | 13621979227 | qli@yafocapital.com

Recent Transaction

YAFO Upcoming Events - ACCESS CHINA Biotech Forum -Winter Showcase (January 4-13, 2021, @JPM Week 2022)

雅法药通中国冬季路演活动将于2022年1月JPM WEEK期间举行。

Please email Wendi Xiang, wxiang@yafocapital.com, if you want to present or attend our winter partnering event.